EMCURE PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of EMCURE PHARMACEUTICALS have increased by 18.59% YoY .
The Earnings Per Share (EPS) of EMCURE PHARMACEUTICALS has increased by 35.60 % YoY. |
||
EMCURE PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 544210|NSE : EMCURE]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹7,896 Cr | ₹6,658 Cr | ₹5,986 Cr | ₹5,855 Cr | ₹6,056 Cr |
| Expenses | ₹6,427 Cr | ₹5,429 Cr | ₹4,805 Cr | ₹4,525 Cr | ₹4,824 Cr |
| Operating Profit (Excl OI) | ₹1,469 Cr | ₹1,230 Cr | ₹1,181 Cr | ₹1,330 Cr | ₹1,232 Cr |
| Other Income | ₹73 Cr | ₹57 Cr | ₹46 Cr | ₹63 Cr | ₹35 Cr |
| Interest | ₹176 Cr | ₹237 Cr | ₹214 Cr | ₹176 Cr | ₹198 Cr |
| Depreciation | ₹384 Cr | ₹312 Cr | ₹260 Cr | ₹245 Cr | ₹323 Cr |
| Profit Before Tax | ₹971 Cr | ₹727 Cr | ₹747 Cr | ₹973 Cr | ₹657 Cr |
| Profit After Tax | ₹707 Cr | ₹528 Cr | ₹562 Cr | ₹703 Cr | ₹419 Cr |
| Consolidated Net Profit | ₹681 Cr | ₹498 Cr | ₹532 Cr | ₹662 Cr | ₹392 Cr |
| Earnings Per Share (Rs) | ₹48.76 | ₹35.96 | ₹27.50 | ₹29.42 | ₹36.62 |
| PAT Margin (%) | 10.02 | 8.82 | 7.77 | 9.21 | 11.75 |
| ROE(%) | 20.09 | 19.19 | 19.45 | 25.21 | 33.19 |
| ROCE(%) | 25.25 | 22.49 | 19.87 | 21.97 | 26.56 |
| Total Debt/Equity(x) | 0.24 | 0.17 | 0.71 | 0.88 | 1.05 |
Key Financials |
||
| Market Cap | : | ₹ 36,870.1 Cr |
| Revenue (TTM) | : | ₹ 9,683.5 Cr |
| Net Profit(TTM) | : | ₹ 1,019.0 Cr |
| EPS (TTM) | : | ₹ 53.7 |
| P/E (TTM) | : | 36.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| EMCURE PHARMACEUTICALS | -0.1% | 5.3% | 46.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.4% | -6.2% | 11.8% |
| DIVIS LABORATORIES | -3.3% | 1.4% | 57.4% |
| TORRENT PHARMACEUTICALS | -4.5% | -4% | 35.9% |
| CIPLA | -3.6% | -5% | -10.6% |
| DR REDDYS LABORATORIES | -0.2% | 2.5% | -3% |
| MANKIND PHARMA | 2.1% | 7.1% | -0.6% |
| LUPIN | -2.9% | -5.6% | 4.1% |
| ZYDUS LIFESCIENCES | -4.7% | -1.6% | 14.2% |
EMCURE PHARMACEUTICALS Revenues
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 18.59 % |
| 5 Yr CAGR | 6.86 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹7,896 Cr | 18.59 | |
| Mar2025 | ₹6,658 Cr | 11.23 | |
| Mar2024 | ₹5,986 Cr | 2.23 | |
| Mar2023 | ₹5,855 Cr | -3.32 | |
| Mar2022 | ₹6,056 Cr | - | |
EMCURE PHARMACEUTICALS Operating Profit
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 19.45 % |
| 5 Yr CAGR | 4.49 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,469 Cr | 19.45 | |
| Mar2025 | ₹1,230 Cr | 4.11 | |
| Mar2024 | ₹1,181 Cr | -11.18 | |
| Mar2023 | ₹1,330 Cr | 7.95 | |
| Mar2022 | ₹1,232 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 0.70 % |
| 5 Yr CAGR | -2.21 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 18.6% | 0.70 | |
| Mar2025 | 18.47% | -6.39 | |
| Mar2024 | 19.73% | -13.12 | |
| Mar2023 | 22.71% | 11.65 | |
| Mar2022 | 20.34% | - | |
EMCURE PHARMACEUTICALS Profit After Tax
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 36.76 % |
| 5 Yr CAGR | 14.81 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹681 Cr | 36.76 | |
| Mar2025 | ₹498 Cr | -6.36 | |
| Mar2024 | ₹532 Cr | -19.66 | |
| Mar2023 | ₹662 Cr | 68.87 | |
| Mar2022 | ₹392 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 13.61 % |
| 5 Yr CAGR | -3.90 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 10.02 % | 13.61 | |
| Mar2025 | 8.82 % | 13.51 | |
| Mar2024 | 7.77 % | -15.64 | |
| Mar2023 | 9.21 % | -21.62 | |
| Mar2022 | 11.75 % | - | |
EMCURE PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 35.60 % |
| 5 Yr CAGR | 7.42 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹49 | 35.60 | |
| Mar2025 | ₹36 | 30.76 | |
| Mar2024 | ₹28 | -6.53 | |
| Mar2023 | ₹29 | -19.66 | |
| Mar2022 | ₹37 | - | |
EMCURE PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 12.27 % |
| 5 Yr CAGR | -1.26 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 25.25% | 12.27 | |
| Mar2025 | 22.49% | 13.19 | |
| Mar2024 | 19.87% | -9.56 | |
| Mar2023 | 21.97% | -17.28 | |
| Mar2022 | 26.56% | - | |
EMCURE PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹1,943.6 |
| Current MarketCap | : | ₹ 36,870.1 Cr |
| Updated EOD on | : | Oct 01,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| EMCURE PHARMACEUTICALS | -0.1% |
5.3% |
46.4% |
| SENSEX | -2.3% |
-6.6% |
-12% |
EMCURE PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 1000 | -2.9% | -6.2% | -5% |
| BSE 500 | -3% | -6.5% | -6% |
| BSE 250 SMALLCAP INDEX | -3.3% | -4.4% | 0.7% |
| BSE 400 MIDSMALLCAP INDEX | -3.6% | -6.5% | -0.3% |
| BSE HEALTHCARE | -3.8% | -3.2% | 12.6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 500 | -2.7% | -3.7% | NA |
| NIFTY500 SHARIAH | -2.8% | -7.1% | -7.7% |
| NIFTY TOTAL MARKET | -3% | -6.6% | -5.1% |
| NIFTY 500 | -3.1% | -6.8% | -5.7% |
| NIFTY SMALLCAP 250 | -3.1% | -4.3% | 2.5% |
You may also like the below Video Courses
FAQ about EMCURE PHARMACEUTICALS Financials
How the annual revenues of EMCURE PHARMACEUTICALS have changed ?
The Revenues of EMCURE PHARMACEUTICALS have increased by 18.59% YoY .
How the Earnings per Share (EPS) of EMCURE PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of EMCURE PHARMACEUTICALS has increased by 35.60 % YoY .
Check out Intrinsic Value of Peers of EMCURE PHARMACEUTICALS
Compare Stock Analytics of Peers of EMCURE PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
